Literature DB >> 28298270

Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease.

Christine C Hsu1, Erik Ness, Kris V Kowdley2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) can range in spectrum from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which is characterized by lipotoxicity, hepatocellular ballooning, and inflammation and can progress to cirrhosis. Weight loss is the cornerstone treatment for NAFLD and NASH. Various randomized controlled trials have shown that weight loss of ≥5-10% leads to significant improvements in hepatic steatosis. Diets high in sodium and fructose have been implicated in the pathogenesis of NAFLD. Although some clinical studies suggest that an isocaloric high-fructose diet does not worsen NAFLD, these clinical studies are often short in duration. More recently, the Dietary Approaches to Stop Hypertension diet, a sodium-restricted diet, has been associated with less prevalence of NAFLD and has been shown to improve NAFLD. In addition, the Mediterranean diet has been promising in improving hepatic steatosis, and a larger randomized controlled trial is currently enrolling subjects. For those who are unable to pursue weight loss through dietary approaches, bariatric surgery has been shown to improve hepatic steatosis and steatohepatitis. This method has been variable in improving hepatic fibrosis. In conclusion, weight loss is crucial to the improvement of NAFLD and NASH, and patients should attempt various diets in an attempt to achieve weight loss.
© 2017 American Society for Nutrition.

Entities:  

Keywords:  DASH diet; bariatric surgery; liver disease; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obesity; type 2 diabetes

Mesh:

Year:  2017        PMID: 28298270      PMCID: PMC5347099          DOI: 10.3945/an.116.013730

Source DB:  PubMed          Journal:  Adv Nutr        ISSN: 2161-8313            Impact factor:   8.701


  114 in total

1.  The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.

Authors:  David Tendler; Sauyu Lin; William S Yancy; John Mavropoulos; Pam Sylvestre; Don C Rockey; Eric C Westman
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

Review 2.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis.

Authors:  Francesco Sofi; Rosanna Abbate; Gian Franco Gensini; Alessandro Casini
Journal:  Am J Clin Nutr       Date:  2010-09-01       Impact factor: 7.045

3.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

4.  Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults.

Authors:  Marno Celeste Ryan; Fahim Abbasi; Cindy Lamendola; Susan Carter; Tracey Lynn McLaughlin
Journal:  Diabetes Care       Date:  2007-03-10       Impact factor: 19.112

5.  Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial.

Authors:  Hilde Risstad; Torgeir T Søvik; My Engström; Erlend T Aasheim; Morten W Fagerland; Monika Fagevik Olsén; Jon A Kristinsson; Carel W le Roux; Thomas Bøhmer; Kåre I Birkeland; Tom Mala; Torsten Olbers
Journal:  JAMA Surg       Date:  2015-04       Impact factor: 14.766

Review 6.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

Authors:  Rajasekhara R Mummadi; Krishna S Kasturi; Swapna Chennareddygari; Gagan K Sood
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

Review 7.  Nutritional deficiencies in obesity and after bariatric surgery.

Authors:  Stavra A Xanthakos
Journal:  Pediatr Clin North Am       Date:  2009-10       Impact factor: 3.278

8.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

Authors:  Laura H Tetri; Metin Basaranoglu; Elizabeth M Brunt; Lisa M Yerian; Brent A Neuschwander-Tetri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

9.  Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study.

Authors:  Hongmei Yan; Mingfeng Xia; Xinxia Chang; Qiong Xu; Hua Bian; Mengsu Zeng; Shengxiang Rao; Xiuzhong Yao; Yinfang Tu; Weiping Jia; Xin Gao
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

10.  A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol.

Authors:  Elena S Papamiltiadous; Stuart K Roberts; Amanda J Nicoll; Marno C Ryan; Catherine Itsiopoulos; Agus Salim; Audrey C Tierney
Journal:  BMC Gastroenterol       Date:  2016-02-02       Impact factor: 3.067

View more
  14 in total

1.  Differential capability of metabolic substrates to promote hepatocellular lipid accumulation.

Authors:  Ngoc Anh Hoang; Friederike Richter; Martin Schubert; Stefan Lorkowski; Lars-Oliver Klotz; Holger Steinbrenner
Journal:  Eur J Nutr       Date:  2018-10-27       Impact factor: 5.614

2.  Organization of future training in bariatric gastroenterology.

Authors:  Timothy R Koch; Timothy R Shope; Christopher J Gostout
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

3.  Anti-Obesity Effect of Chitosan Oligosaccharide Capsules (COSCs) in Obese Rats by Ameliorating Leptin Resistance and Adipogenesis.

Authors:  Haitao Pan; Chuhan Fu; Lanlan Huang; Yao Jiang; Xiaoyi Deng; Jiao Guo; Zhengquan Su
Journal:  Mar Drugs       Date:  2018-06-05       Impact factor: 5.118

4.  Hepatoprotective Effects of Insect Extracts in an Animal Model of Nonalcoholic Fatty Liver Disease.

Authors:  A-Rang Im; Won-Kyung Yang; Yang-Chun Park; Seung Hyung Kim; Sungwook Chae
Journal:  Nutrients       Date:  2018-06-07       Impact factor: 5.717

5.  Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study.

Authors:  Chloe E Panizza; Unhee Lim; Kim M Yonemori; Kevin D Cassel; Lynne R Wilkens; Michelle N Harvie; Gertraud Maskarinec; Edward J Delp; Johanna W Lampe; John A Shepherd; Loïc Le Marchand; Carol J Boushey
Journal:  Nutrients       Date:  2019-06-20       Impact factor: 5.717

Review 6.  Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date.

Authors:  Małgorzata Moszak; Monika Szulińska; Marta Walczak-Gałęzewska; Paweł Bogdański
Journal:  Int J Environ Res Public Health       Date:  2021-02-08       Impact factor: 3.390

Review 7.  The Significance of the Mediterranean Diet in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Harpreet Gosal; Harsimran Kaur; Hyginus Chakwop Ngassa; Khaled A Elmenawi; Vishwanath Anil; Lubna Mohammed
Journal:  Cureus       Date:  2021-06-13

8.  Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease.

Authors:  Federico Salomone; Dana Ivancovsky-Wajcman; Naomi Fliss-Isakov; Muriel Webb; Giuseppe Grosso; Justyna Godos; Fabio Galvano; Oren Shibolet; Revital Kariv; Shira Zelber-Sagi
Journal:  JHEP Rep       Date:  2020-01-28

9.  Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Christina N Katsagoni; Eleftheria Papachristou; Amalia Sidossis; Labros Sidossis
Journal:  Nutrients       Date:  2020-09-19       Impact factor: 5.717

Review 10.  Metabolic drivers of non-alcoholic fatty liver disease.

Authors:  Kendra K Bence; Morris J Birnbaum
Journal:  Mol Metab       Date:  2020-12-17       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.